pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['bladder', 'ev103', ' ev ', 'ev302', 'pembro']
#ev103 cohort k presented by the amazing ev + pembro vs ev in metastatic #bladdercancer shows impressive objective response rate 64.5%! forms basis for 1st line ev302 trial. #esmo22 
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe